Roche launches Bluetooth-enabled self-testing device to check blood clotting in EU
Swiss drug firm Roche (Six: ROG) has launched a blood-clott monitoring system for patients with different heart conditions.
The CoaguChek INRange system is a Bluetooth enabled home health device that helps patients and their healthcare providers (HCP) monitor coagulation status and the ability to monitor Vitamin K Antagonist (VKA) therapy, the company said in a statement.
Roland Diggelmann, chief operating officer, Roche Diagnostics, said: “As healthcare systems face continued pressure to deliver improved access to care at a lower cost, increased connectivity between HCPs and patients becomes even more important. This innovative technology continues the CoaguChek legacy of setting the standard in coagulation monitoring by providing high quality, convenient care, while optimising outcomes for patients. This is another proof point towards our aim to position patient self-testing as the standard of care to monitor VKA therapy.”
Vitamin K Antagonists (VKAs) are indicated to patients for a variety of conditions, including atrial fibrillation (AF), deep vein thrombosis (DVT), pulmonary embolism (PE), and the presence of a mechanical heart valve (MHV).
To best monitor the efficacy of VKAs, the prothrombin time PT (INR) needs to be frequently measured.
Roche has announced that the US Food and Drug Administration (FDA) has approved Vabysmo (farcimab) …
Roche has announced that it has entered into a definitive agreement to acquire Telavant Holdings, …